Skip to main content
. 2022 Mar 3;12:842182. doi: 10.3389/fonc.2022.842182

Table 1.

Patient and tumor characteristics.

Variable BCG treatment
Age (years)
 50–59 7/24 (29.2%)
 60–69 8/24 (33.3%)
 70–79 9/24 (37.5%)
Gender
 Male 21/24 (87.5%)
 Female 3/24 (12.5%)
No. of tumors
 Single 10/24 (41.7%)
 Multiple 14/24 (58.3%)
Tumor size (d/cm)
 0–3 15/24 (62.5%)
 ≥3 9/24 (37.5%)
T category
 Ta 13/24 (54.2%)
 T1 11/24 (45.8%)
Grade
 G2 10/24 (41.7%)
 G3 14/24 (58.3%)
CIS
 Yes 5/24 (20.8%)
 No 19/24 (79.2%)
EORTC recurrence score
 ≤9 (intermediate risk) 22/24 (91.7%)
 10–17 (high risk) 2/24 (8.3%)
EORTC progression score
  ≤6 (intermediate risk) 10/24 (41.7%)
 7–23 (high risk) 14/24 (58.3%)